Great Debates and Updates in Breast Cancer 2010

Who Should Attend

This educational activity is specifically designed for medical oncologists, radiation oncologists, breast cancer specialists, surgical oncologists, pathologists and other allied healthcare professionals involved in the management of breast cancer.

 
Objectives

After successful completion of this educational activity, attendees should be able to:

-Determine how novel strategies in the surgical management of breast cancer and new recommendations for post-surgery therapy can improve patient outcomes

-Evaluate whether intense surveillance techniques should be conducted to adequately assess recurrence of risk and individualization of breast cancer therapy

-Identify the new predictive factors for determining intrinsic resistance for various therapeutic strategies in breast cancer

-Comment on emerging research in genetic profiling and biomarkers for breast cancer that can influence choice of therapy

-Interpret and integrate recent clinical trial data on emerging agents for the prevention and treatment of localized and metastatic breast cancer including anti-HER2 agents, anti-tubulin agents, and bisphosphonates

-Summarize optimal hormonal therapy for ER+ stage breast cancer

-Adequately address controversial questions in the optimal use of anti-HER2 agents, including recommendations for early stage HER2+ breast cancer, therapeutic strategies following disease progression, and approaches to combat anti-HER2 resistance

-ategies in the surgical management of breast cancer and new recommendations for post-surgery therapy can improve patient outcomes